Mechanisms of Multidrug Resistance in Cancer Chemotherapy

Synthesis of N‐Carbonyl Acridanes as Highly Potent Inhibitors of Tubulin Polymerization via One‐Pot Copper‐Catalyzed Dual Arylation of Nitriles with Cyclic Diphenyl Iodoniums

(2020) Xiaopeng Peng et al.   ADVANCED SYNTHESIS & CATALYSIS

microRNA-499a promotes the progression and chemoresistance of cervical cancer cells by targeting SOX6

(2020) Yibing Chen et al.   APOPTOSIS

Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells

(2020) Seiichi Okabe et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The Effects of TiO2 Nanoparticles on Cisplatin Cytotoxicity in Cancer Cell Lines

(2020) Basma Salama et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Structure-Guided Optimization of Replication Protein A (RPA)–DNA Interaction Inhibitors

(2020) Navnath S. Gavande et al.   ACS Medicinal Chemistry Letters

Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs

(2020) Chung-Pu Wu et al.   Cancers

Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors

(2020) Sabrina Dallavalle et al.   DRUG RESISTANCE UPDATES

Erastin decreases radioresistance of NSCLC cells partially by inducing GPX4‑mediated ferroptosis

(2019) Xiaofen Pan et al.   Oncology Letters

The role and mechanisms of action of microRNAs in cancer drug resistance

(2019) Wengong Si et al.   Clinical Epigenetics

Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients

(2019) Chodimella Chandrasekhar et al.   Scientific Reports

Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer

(2019) Helai P. Mohammad et al.   NATURE MEDICINE

Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers

(2019) Hideaki Ogiwara et al.   CANCER CELL

Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis

(2019) Mohamed Elgendy et al.   CANCER CELL

Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer

(2019) In-Hye Ham et al.   Molecular Cancer

Pharmacological boost of DNA damage response and repair by enhanced biogenesis of DNA damage response RNAs

(2019) Ubaldo Gioia et al.   Scientific Reports

A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy

(2019) Jessica L. Wojtaszek et al.   CELL

Ascorbate promotes the cellular accumulation of doxorubicin and reverses the multidrug resistance in breast cancer cells by inducing ROS-dependent ATP depletion

(2019) Yutong Liu et al.   FREE RADICAL RESEARCH

DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion

(2019) Benjamin D. Bax et al.   JOURNAL OF MOLECULAR BIOLOGY

Reactive OFF-ON type alkylating agents for higher-ordered structures of nucleic acids

(2019) Kazumitsu Onizuka et al.   NUCLEIC ACIDS RESEARCH

Unraveling the Potential Role of Glutathione in Multiple Forms of Cell Death in Cancer Therapy

(2019) Huanhuan Lv et al.   Oxidative Medicine and Cellular Longevity

Drugs Targeting Epigenetic Modifications and Plausible Therapeutic Strategies Against Colorectal Cancer

(2019) Srinivas Patnaik et al.   Frontiers in Pharmacology

Amplification of the CD24 Gene Is an Independent Predictor for Poor Prognosis of Breast Cancer

(2019) Peng Zhang et al.   Frontiers in Genetics

Fibroblast Growth Factor Receptor Functions in Glioblastoma

(2019) Ana Jimenez-Pascual et al.   Cells

Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study

(2019) Ya-Chen Tina Shih et al.   Lancet Haematology

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

(2019) Jacqueline H. L. Fok et al.   Nature Communications

Targeting Glutathione Metabolism: Partner in Crime in Anticancer Therapy

(2019) Enrico Desideri et al.   Nutrients

Computer‐aided drug design of small molecule inhibitors of the ERCC1‐XPF protein–protein interaction

(2019) Francesco Gentile et al.   Chemical Biology & Drug Design

Enabling P-glycoprotein inhibition in multidrug resistant cancer through the reverse targeting of a quinidine-PEG conjugate

(2019) Sarah Snyder et al.   JOURNAL OF CONTROLLED RELEASE

Drug metabolizing enzymes and their inhibitors' role in cancer resistance

(2018) Shelly Pathania et al.   BIOMEDICINE & PHARMACOTHERAPY

Glutathione in Ovarian Cancer: A Double-Edged Sword

(2018) Sofia Nunes et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Evaluation of chalcones as inhibitors of glutathione S-transferase

(2018) Muhammet Serhat Özaslan et al.   JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY

Glutathione metabolism in cancer progression and treatment resistance

(2018) Ankita Bansal et al.   JOURNAL OF CELL BIOLOGY

Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences

(2018) Lorena Infante Lara et al.   NUCLEIC ACIDS RESEARCH

MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer

(2018) Hui-Ming Lin et al.   Scientific Reports

Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells

(2018) Amila K. Nanayakkara et al.   Scientific Reports

A Study on Effect of Oxaliplatin in MicroRNA Expression in Human Colon Cancer

(2018) Jasmine Evert et al.   Journal of Cancer

Ferroptosis-inducing agents enhance TRAIL-induced apoptosis through upregulation of death receptor 5

(2018) Young-Sun Lee et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Crown ethers reverse P-glycoprotein-mediated multidrug resistance in cancer cells

(2018) Iva Guberović et al.   Scientific Reports

Mutant p53 as a guardian of the cancer cell

(2018) Fiamma Mantovani et al.   CELL DEATH AND DIFFERENTIATION

DNA repair pathways and cisplatin resistance: an intimate relationship

(2018) CR Rocha et al.   Clinics

Anticancer Activity of Natural Compounds from Plant and Marine Environment

(2018) Anna Lichota et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Overcoming Drug Resistance through the Development of Selective Inhibitors of UDP-Glucuronosyltransferase Enzymes

(2018) Michael J. Osborne et al.   JOURNAL OF MOLECULAR BIOLOGY

Taxifolin Resensitizes Multidrug Resistance Cancer Cells via Uncompetitive Inhibition of P-Glycoprotein Function

(2018) Hsiu-Ju Chen et al.   MOLECULES

MicroRNA-495-3p inhibits multidrug resistance by modulating autophagy through GRP78/mTOR axis in gastric cancer

(2018) Sheng Chen et al.   Cell Death & Disease

Tumor-related interleukins: old validated targets for new anti-cancer drug development

(2017) Sarra Setrerrahmane et al.   Molecular Cancer

Reversal of P-gp-mediated multidrug resistance in colon cancer by cinobufagin

(2017) Zeting Yuan et al.   ONCOLOGY REPORTS

Inhibition of human erythrocyte glutathione S-transferase by some flavonoid derivatives

(2017) Mine Aksoy et al.   Toxin Reviews

Tomentodione M sensitizes multidrug resistant cancer cells by decreasing P-glycoprotein via inhibition of p38 MAPK signaling

(2017) Xu-Wei Zhou et al.   Oncotarget

Novel strategies to prevent the development of multidrug resistance (MDR) in cancer

(2017) Jinglu Wang et al.   Oncotarget

Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis

(2017) Pin-Fang He et al.   Oncotarget

Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?

(2017) Kinrin Yamanaka et al.   PLoS Genetics

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

(2017) et al.   JAMA Oncology

Tumoral expression of drug and xenobiotic metabolizing enzymes in breast cancer patients of different ethnicities with implications to personalized medicine

(2017) Yan Li et al.   Scientific Reports

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells

(2016) Aparajitha Vaidyanathan et al.   BRITISH JOURNAL OF CANCER

MicroRNA-125b Suppresses Ovarian Cancer Progression via Suppression of the Epithelial-Mesenchymal Transition Pathway by Targeting the SET Protein

(2016) Xiaoyan Ying et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression

(2016) Jing Yan et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma

(2016) Judith G. Villablanca et al.   PEDIATRIC BLOOD & CANCER

Pharmacogenomics and histone deacetylase inhibitors

(2016) Andrew KL Goey et al.   PHARMACOGENOMICS

Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression

(2016) Jiang Zhu et al.   Cell Death & Disease

MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression

(2016) Z Fan et al.   Oncogenesis

MicroRNA-320a promotes 5-FU resistance in human pancreatic cancer cells

(2016) Weibin Wang et al.   Scientific Reports

Human ABCB1 confers cells resistance to cytotoxic guanidine alkaloids from Pterogyne nitens

(2015) Kazuhiro Satake et al.   BIO-MEDICAL MATERIALS AND ENGINEERING

Chemical inhibitor targeting the replication protein A–DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer

(2015) Akaash K. Mishra et al.   BIOCHEMICAL PHARMACOLOGY

Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF

(2015) Timothy M. Chapman et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1

(2015) Lin Lu et al.   BIOTECHNOLOGY LETTERS

Inhibition of the ERCC1–XPF structure-specific endonuclease to overcome cancer chemoresistance

(2015) Ewan M. McNeil et al.   DNA REPAIR

Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL

(2015) Paloma S. Souza et al.   EXPERIMENTAL CELL RESEARCH

Exploiting a novel miR-519c–HuR–ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer

(2015) Kenneth K.W. To et al.   EXPERIMENTAL CELL RESEARCH

Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death

(2015) Daniela Catanzaro et al.   Oncotarget

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients

(2015) Leticia De Mattos-Arruda et al.   Oncotarget

The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo

(2015) Frank P. Vendetti et al.   Oncotarget

MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin

(2015) Zhiyu Wang et al.   Oncotarget

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

(2015) Amy B. Hall et al.   Oncotarget

Indirect modulation of sensitivity to 5-fluorouracil by microRNA-96 in human colorectal cancer cells

(2014) Sun-Ah Kim et al.   ARCHIVES OF PHARMACAL RESEARCH

Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches

(2014) Qiong Wu et al.   CANCER LETTERS

Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors

(2014) T. Shimizu et al.   CLINICAL CANCER RESEARCH

Targeting DNA repair pathways for cancer treatment: what’s new?

(2014) Mark R Kelley et al.   Future Oncology

Multiple roles of extracellular fibroblast growth factors in lung cancer cells

(2014) TAKAHIRO SUZUKI et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

A Small Molecule Inhibitor of Monoubiquitinated Proliferating Cell Nuclear Antigen(PCNA) Inhibits Repair of Interstrand DNA Cross-link, Enhances DNA Double Strand Break, and Sensitizes Cancer Cells to Cisplatin

(2014) Akira Inoue et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy

(2014) Nada Albarakati et al.   Molecular Oncology

Effects of P-Glycoprotein and Its Inhibitors on Apoptosis in K562 Cells

(2014) Yaqiong Zu et al.   MOLECULES

The role of ABC transporters in anticancer drug transport

(2014) Serhan KARVAR   TURKISH JOURNAL OF BIOLOGY

Glutathione S-conjugates as prodrugs to target drug-resistant tumors

(2014) Emma E. Ramsay et al.   Frontiers in Pharmacology

A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin

(2014) David A. Alagpulinsa et al.   Frontiers in Oncology

P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway

(2013) Hanan Galski et al.   BIOCHEMICAL PHARMACOLOGY

miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1

(2013) Y Shang et al.   ONCOGENE

miRNA profiling in pancreatic cancer and restoration of chemosensitivity

(2012) Saurabh Singh et al.   CANCER LETTERS

Epigenetic modifications in cancer

(2011) R Kanwal et al.   CLINICAL GENETICS

Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells

(2011) Yue Wang et al.   CYTOKINE

Novel Irreversible Small Molecule Inhibitors of Replication Protein A Display Single-Agent Activity and Synergize with Cisplatin

(2011) T. M. Neher et al.   MOLECULAR CANCER THERAPEUTICS

Analysis of anticancer drugs: A review

(2011) Susanne Nussbaumer et al.   TALANTA

P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 Determine the Pharmacokinetics of Etoposide

(2009) J. S. Lagas et al.   CLINICAL CANCER RESEARCH

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma

(2009) Jennifer Wu et al.   INVESTIGATIONAL NEW DRUGS

Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients

(2008) Suman Lal et al.   CANCER SCIENCE